Author:
Rini B.I.,Melichar B.,Fishman M.N.,Oya M.,Pithavala Y.K.,Chen Y.,Bair A.H.,Grünwald V.
Reference12 articles.
1. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3;Hu-Lowe;Clin Cancer Res,2008
2. Inlyta® (axitinib) prescribing information. http://labeling.pfizer.com/ShowLabeling.aspx?id=759 (25 July 2014, date last accessed).
3. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer;Faivre;J Clin Oncol,2006
4. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors;Strumberg;Oncologist,2007
5. Phase I trial of pazopanib in patients with advanced cancer;Hurwitz;Clin Cancer Res,2009
Cited by
69 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献